Serena J. Silver

Accent Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index14.6kcitations117works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(20), Science, Research, and Medicine(20), RNA and protein synthesis mechanisms(17), RNA Research and Splicing(17), RNA modifications and cancer(15)

Publications117 total

The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells
Cells·2025Open Access
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement
ACS Medicinal Chemistry Letters·2025· 1 cited
Abstract B045: ATX-559, a first-in-class, clinical-stage DHX9 inhibitor, as a targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress
Molecular Cancer Therapeutics·2025
Abstract B122: Activity of the novel KIF18A Inhibitor, ATX-295, is enriched in whole genome doubled ovarian and TNBC preclinical models
Molecular Cancer Therapeutics·2025
Abstract A031: DHX9 inhibition induces genomic instability and enhances paclitaxel sensitivity in drug-resistant high-grade serous ovarian cancer (HGSOC) cells
Cancer Research·2025
Abstract B024: Investigating a novel KIF18A inhibitor ATX020 in chromosomally instable ovarian cancer
Cancer Research·2025
Trial in progress: First-in-human study of ATX-559, an oral inhibitor of DHX9, in patients with advanced or metastatic solid tumors, and molecularly defined cancers.
Journal of Clinical Oncology·2025
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9
Journal of Medicinal Chemistry·2025· 6 citedOpen Access
Abstract 1758: ATX-559, a first in class DHX9 inhibitor, and targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress
Cancer Research·2025· 1 cited
Abstract 3784: Activity of the novel KIF18A inhibitor, ATX-295, is enriched in whole genome doubled ovarian cancer pre-clinical models
Cancer Research·2025· 1 cited
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3’,5’-bisphosphate as a potent enzyme inhibitor
Communications Biology·2025Open Access
Supplementary Data Figure 2 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 2 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 3 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Table 2 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 4 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 4 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Table 3 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 1 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Table 1 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
page 1 of 6Next →

Frequent Co-authors

David E. Root(20), William C. Hahn(11), Jesse S. Boehm(10), Stephen J. Blakemore(9), P. Ann Boriack‐Sjodin(9), Kenneth W. Duncan(9), Robert A. Copeland(9), So Young Kim(8), Anna C. Schinzel(7), Deepali Gotur(7), Brian A. Sparling(7), Ian F. Dunn(6), William R. Sellers(6), Ilaria Rebay(6), Shane M. Buker(6), Scott Ribich(6), David A. Barbie(5), Tyler Jacks(5), Jennifer Castro(5), Matthew H. Daniels(5)